{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:27:57Z","timestamp":1772782077701,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Oriental Talent Youth Project","award":["CYON2023017"],"award-info":[{"award-number":["CYON2023017"]}]},{"name":"Medical and Health Project of People's Livelihood Research of Shanghai Pudong New Area","award":["PKJ2023-Y01"],"award-info":[{"award-number":["PKJ2023-Y01"]}]},{"name":"Key Discipline Construction Project of Shanghai Pudong New Area","award":["PWZxk2022-07"],"award-info":[{"award-number":["PWZxk2022-07"]}]},{"name":"Talents Training Program of the Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine","award":["BDX2022-01"],"award-info":[{"award-number":["BDX2022-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01488-2","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:15:42Z","timestamp":1734765342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy"],"prefix":"10.1007","author":[{"given":"Siyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiansi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kourong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuzhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beiwei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"1488_CR1","doi-asserted-by":"publisher","first-page":"153303382311784","DOI":"10.1177\/15330338231178403","volume":"22","author":"A Dey","year":"2023","unstructured":"Dey A, Mitra A, Pathak S et al (2023) Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer. Technol Cancer Res Treat 22:15330338231178404. https:\/\/doi.org\/10.1177\/15330338231178403","journal-title":"Technol Cancer Res Treat"},{"issue":"2","key":"1488_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","volume":"347","author":"Q Wu","year":"2014","unstructured":"Wu Q, Yang Z, Nie Y, Shi Y, Fan D (2014) Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347(2):159\u201366. https:\/\/doi.org\/10.1016\/j.canlet.2014.03.013","journal-title":"Cancer Lett"},{"issue":"7","key":"1488_CR3","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1021\/cr900208x","volume":"109","author":"DS Shewach","year":"2009","unstructured":"Shewach DS, Kuchta RD (2009) Introduction to cancer chemotherapeutics. Chem Rev 109(7):2859\u201361. https:\/\/doi.org\/10.1021\/cr900208x","journal-title":"Chem Rev"},{"issue":"2","key":"1488_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.2023046835","volume":"28","author":"R Shah","year":"2023","unstructured":"Shah R, Shah H, Thakkar K, Parikh N (2023) Conventional therapies of oral cancers: highlights on chemotherapeutic agents and radiotherapy, their adverse effects, and the cost burden of conventional therapies. Crit Rev Oncog 28(2):1\u201310. https:\/\/doi.org\/10.1615\/CritRevOncog.2023046835","journal-title":"Crit Rev Oncog"},{"issue":"3","key":"1488_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12032-023-01954-6","volume":"40","author":"Lee SH Brianna","year":"2023","unstructured":"Brianna Lee SH (2023) Chemotherapy: how to reduce its adverse effects while maintaining the potency? Med Oncol 40(3):88. https:\/\/doi.org\/10.1007\/s12032-023-01954-6","journal-title":"Med Oncol"},{"issue":"6","key":"1488_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","volume":"31","author":"PM Drake","year":"2017","unstructured":"Drake PM, Rabuka D (2017) Recent developments in ADC technology: preclinical studies signal future clinical trends. BioDrugs 31(6):521\u2013531. https:\/\/doi.org\/10.1007\/s40259-017-0254-1","journal-title":"BioDrugs"},{"key":"1488_CR7","doi-asserted-by":"publisher","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP (2023) Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel) 15(3). https:\/\/doi.org\/10.3390\/cancers15030713","DOI":"10.3390\/cancers15030713"},{"key":"1488_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-541-5_1","volume":"1045","author":"I Sassoon","year":"2013","unstructured":"Sassoon I, Blanc V (2013) Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol 1045:1\u201327. https:\/\/doi.org\/10.1007\/978-1-62703-541-5_1","journal-title":"Methods Mol Biol"},{"issue":"11","key":"1488_CR9","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","volume":"32","author":"N Jain","year":"2015","unstructured":"Jain N, Smith SW, Ghone S, Tomczuk B (2015) Current ADC linker chemistry. Pharm Res 32(11):3526\u201340. https:\/\/doi.org\/10.1007\/s11095-015-1657-7","journal-title":"Pharm Res"},{"issue":"1","key":"1488_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","volume":"235","author":"S Yaghoubi","year":"2020","unstructured":"Yaghoubi S, Karimi MH, Lotfinia M et al (2020) Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol 235(1):31\u201364. https:\/\/doi.org\/10.1002\/jcp.28967","journal-title":"J Cell Physiol"},{"issue":"9","key":"1488_CR11","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","volume":"13","author":"L Gong","year":"2023","unstructured":"Gong L, Zhao H, Liu Y et al (2023) Research advances in peptide-drug conjugates. Acta Pharm Sin B 13(9):3659\u20133677. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.013","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"1488_CR12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1039\/d0cs00556h","volume":"50","author":"BM Cooper","year":"2021","unstructured":"Cooper BM, Iegre J, O\u2019Donovan DH, \u00d6lweg\u00e5rdHalvarsson M, Spring DR (2021) Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem Soc Rev 50(3):1480\u20131494. https:\/\/doi.org\/10.1039\/d0cs00556h","journal-title":"Chem Soc Rev"},{"issue":"2","key":"1488_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","volume":"13","author":"C Fu","year":"2023","unstructured":"Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M (2023) Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B 13(2):498\u2013516. https:\/\/doi.org\/10.1016\/j.apsb.2022.07.020","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"1488_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2217\/fon.14.8","volume":"10","author":"WS Graybill","year":"2014","unstructured":"Graybill WS, Coleman RL (2014) Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol 10(4):541\u20138. https:\/\/doi.org\/10.2217\/fon.14.8","journal-title":"Future Oncol"},{"issue":"4","key":"1488_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1586\/17512433.2014.909723","volume":"7","author":"AJ Ambrosio","year":"2014","unstructured":"Ambrosio AJ, Suzin D, Palmer EL, Penson RT (2014) Vintafolide (EC145) for the treatment of folate-receptor-\u03b1 positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol 7(4):443\u201350. https:\/\/doi.org\/10.1586\/17512433.2014.909723","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"1488_CR16","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T et al (2019) Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol 234(5):5628\u20135642. https:\/\/doi.org\/10.1002\/jcp.27419","journal-title":"J Cell Physiol"},{"issue":"23","key":"1488_CR17","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343\u201351. https:\/\/doi.org\/10.1056\/NEJMoa032709","journal-title":"N Engl J Med"},{"issue":"9","key":"1488_CR18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9","volume":"68","author":"GJ Peters","year":"1991","unstructured":"Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM (1991) A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68(9):1903\u20139. https:\/\/doi.org\/10.1002\/1097-0142(19911101)68:9%3c1903::aid-cncr2820680910%3e3.0.co;2-9","journal-title":"Cancer"},{"issue":"12","key":"1488_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jps.2600691220","volume":"69","author":"TA Phillips","year":"1980","unstructured":"Phillips TA, Howell A, Grieve RJ, Welling PG (1980) Pharmacokinetics of oral and intravenous fluorouracil in humans. J Pharm Sci 69(12):1428\u201331. https:\/\/doi.org\/10.1002\/jps.2600691220","journal-title":"J Pharm Sci"},{"issue":"10","key":"1488_CR20","first-page":"3479","volume":"38","author":"WE MacMillan","year":"1978","unstructured":"MacMillan WE, Wolberg WH, Welling PG (1978) Pharmacokinetics of fluorouracil in humans. Cancer Res. 38(10):3479\u201382","journal-title":"Cancer Res."},{"issue":"5","key":"1488_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000011897","volume":"55","author":"C Katona","year":"1998","unstructured":"Katona C, Kralov\u00e1nszky J, Rosta A et al (1998) Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology 55(5):468\u201374. https:\/\/doi.org\/10.1159\/000011897","journal-title":"Oncology"},{"key":"1488_CR22","doi-asserted-by":"publisher","first-page":"117105","DOI":"10.1016\/j.saa.2019.05.010","volume":"220","author":"Y Wang","year":"2019","unstructured":"Wang Y, Han Q, Zhang H (2019) Evaluation of the toxicity of 5-fluorouracil on three digestive enzymes from the view of side effects. Spectrochim Acta A Mol Biomol Spectrosc 220:117105. https:\/\/doi.org\/10.1016\/j.saa.2019.05.010","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"1488_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.actbio.2018.07.014","volume":"77","author":"M Hou","year":"2018","unstructured":"Hou M, Gao YE, Shi X et al (2018) Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy. Acta Biomater 77:228\u2013239. https:\/\/doi.org\/10.1016\/j.actbio.2018.07.014","journal-title":"Acta Biomater"},{"issue":"7","key":"1488_CR24","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1039\/c8bm00009c","volume":"6","author":"Y Li","year":"2018","unstructured":"Li Y, Zhang H, Chen Y et al (2018) Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy. Biomater Sci 6(7):1818\u20131833. https:\/\/doi.org\/10.1039\/c8bm00009c","journal-title":"Biomater Sci"},{"key":"1488_CR25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2147\/ijn.S152312","volume":"13","author":"J Xie","year":"2018","unstructured":"Xie J, Fan Z, Li Y et al (2018) Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy. Int J Nanomedicine 13:1381\u20131398. https:\/\/doi.org\/10.2147\/ijn.S152312","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"1488_CR26","first-page":"2700","volume":"41","author":"PN Kulkarni","year":"1981","unstructured":"Kulkarni PN, Blair AH, Ghose TI (1981) Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res 41(7):2700\u20136","journal-title":"Cancer Res"},{"issue":"5","key":"1488_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00280-012-2062-0","volume":"71","author":"SS Abolmaali","year":"2013","unstructured":"Abolmaali SS, Tamaddon AM, Dinarvand R (2013) A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol 71(5):1115\u201330. https:\/\/doi.org\/10.1007\/s00280-012-2062-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"40","key":"1488_CR28","doi-asserted-by":"publisher","first-page":"34650","DOI":"10.1021\/acsami.7b10027","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Lin J, Ma J et al (2017) Methotrexate-camptothecin prodrug nanoassemblies as a versatile nanoplatform for biomodal imaging-guided self-active targeted and synergistic chemotherapy. ACS Appl Mater Interfaces 9(40):34650\u201334665. https:\/\/doi.org\/10.1021\/acsami.7b10027","journal-title":"ACS Appl Mater Interfaces"},{"key":"1488_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0065-2571(94)90025-6","volume":"34","author":"FM Huennekens","year":"1994","unstructured":"Huennekens FM (1994) The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 34:397\u2013419. https:\/\/doi.org\/10.1016\/0065-2571(94)90025-6","journal-title":"Adv Enzyme Regul"},{"issue":"17","key":"1488_CR30","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1039\/d0tb00468e","volume":"8","author":"M Chen","year":"2020","unstructured":"Chen M, Chen S, Zhu F et al (2020) \u201cWatson-Crick G[triple bond, length as m-dash]C\u201d-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy. J Mater Chem B 8(17):3829\u20133841. https:\/\/doi.org\/10.1039\/d0tb00468e","journal-title":"J Mater Chem B"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01488-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T08:03:29Z","timestamp":1734768209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":30,"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01488-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animals were housed in a pathogen-free environment at 25 \u00b1 3 \u00b0C with a 12-h light\/dark cycle and had free access to food and water. The animal experiments involved in this article were authorized by the Animal Ethics Committee of Fujian University of Traditional Chinese Medicine (SCXK 2019-0001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}